Cargando…

Pharmacologic inhibition of MIF nuclease: A new treatment paradigm to treat cell death

Detalles Bibliográficos
Autores principales:	Biswas, Devanik, Dawson, Valina L., Dawson, Ted M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488529/ https://www.ncbi.nlm.nih.gov/pubmed/36125899 http://dx.doi.org/10.1002/ctm2.1044

Ejemplares similares

Waiting for PARIS—A Biological Target in Search of a Drug: PARIS farnesylation: Considerations in addressing a new biological target for neuroprotection in patients with Parkinson’s disease
por: Wyse, Richard K., et al.
Publicado: (2022)

4‐Iodopyrimidine Labeling Reveals Nuclear Translocation and Nuclease Activity for Both MIF and MIF2
por: Xiao, Zhangping, et al.
Publicado: (2021)

STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy
por: Hinkle, Jared T., et al.
Publicado: (2022)

IL-16 and MIF: messengers beyond neutrophil cell death
por: Roth, S, et al.
Publicado: (2016)

MIF is a 3’ flap nuclease that facilitates DNA replication and promotes tumor growth
por: Wang, Yijie, et al.
Publicado: (2021)

PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease
por: Ge, Preston, et al.
Publicado: (2020)

The interplay of microRNA and neuronal activity in health and disease
por: Eacker, Stephen M., et al.
Publicado: (2013)

Targeting Parthanatos in Ischemic Stroke
por: Koehler, Raymond C., et al.
Publicado: (2021)

The cell biology of Parkinson’s disease
por: Panicker, Nikhil, et al.
Publicado: (2021)

Two approaches reveal a new paradigm of ‘switchable or genetics-influenced allele-specific DNA methylation’ with potential in human disease
por: Martos, Suzanne N, et al.
Publicado: (2017)

Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin
por: Kam, Tae-In, et al.
Publicado: (2022)

The Economic Costs of Diabetes: Is It Time for a New Treatment Paradigm?
por: Herman, William H.
Publicado: (2013)

DNA Methylation Signature of Aging: Potential Impact on the Pathogenesis of Parkinson’s Disease
por: Yazar, Volkan, et al.
Publicado: (2023)

MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models
por: Fingerle-Rowson, Günter, et al.
Publicado: (2007)

MIF: Mood Improving/Inhibiting Factor?
por: Bloom, Joshua, et al.
Publicado: (2014)

Interculturalism: Not a new policy paradigm
por: Modood, Tariq
Publicado: (2018)

A new paradigm for the management of ATL
por: Taylor, Graham P., et al.
Publicado: (2022)

Should Prediabetes be Treated Pharmacologically?
por: Davidson, Mayer B.
Publicado: (2023)

Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons
por: Yin, Xiling, et al.
Publicado: (2021)

Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-γ associated gene regulation
por: Yazar, Volkan, et al.
Publicado: (2021)

Recent advances in preventing neurodegenerative diseases
por: Chou, Shih-Ching, et al.
Publicado: (2021)

Neuronal Activity Regulates Hippocampal miRNA Expression
por: Eacker, Stephen M., et al.
Publicado: (2011)

Functional Identification of Neuroprotective Molecules
por: Dai, Cheng, et al.
Publicado: (2010)

MiR-223 regulates the differentiation of immature neurons
por: Harraz, Maged M, et al.
Publicado: (2014)

Crossover recombination mediated by HIM-18/SLX4-associated nucleases
por: Saito, Takamune T, et al.
Publicado: (2014)

A New Paradigm of Cardiovascular Risk Factor Modification
por: Firdaus, Muhammad, et al.
Publicado: (2005)

New paradigms in cervical cancer prevention: opportunities and risks
por: Ronco, Guglielmo, et al.
Publicado: (2008)

Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death
por: Cregan, Sean P., et al.
Publicado: (2002)

A MIF‐Derived Cyclopeptide that Inhibits MIF Binding and Atherogenic Signaling via the Chemokine Receptor CXCR2
por: Krammer, Christine, et al.
Publicado: (2020)

The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
por: Karuppagounder, Senthilkumar S., et al.
Publicado: (2014)

Paradigm Shift or Shifting Paradigm for Type 1 Diabetes
por: Nakayama, Maki, et al.
Publicado: (2012)

Will systems biology offer new holistic paradigms to life sciences?
por: Conti, Filippo, et al.
Publicado: (2008)

Open innovation as a new paradigm for global collaborations in health
por: Dandonoli, Patricia
Publicado: (2013)

Aortic Counterpulsation for Myocardial Support: Towards a New Paradigm
por: Choudhury, Arindam
Publicado: (2019)

Drug-based vector control: a potential new paradigm
por: Alonso, Pedro, et al.
Publicado: (2017)

Cyanobacteria provide a new paradigm in the regulation of cofactor dependence
por: Blaby-Haas, Crysten E.
Publicado: (2021)

(R)evolution: toward a new paradigm of policy and patient advocacy for expanded access to experimental treatments
por: Hogan, Melissa
Publicado: (2016)

New Agents in the Management of Type 2 Diabetes: Do They Provide an Opportunity for a Shift in the Treatment Paradigm?
por: Valdez, Connie A.
Publicado: (2008)

Outer mitochondrial membrane localization of apoptosis-inducing factor: mechanistic implications for release
por: Yu, Seong-Woon, et al.
Publicado: (2009)

Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic Activities
por: Yin, Xiling, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d40bq482uvh00839gqdm3kgr07